Sponsor

Universitaetsklinikum Erlangen AöR

Germany Maximiliansplatz 2, Innenstadt, 91054 Erlangen, Germany

About the sponsor

Clinical research at Universitaetsklinikum Erlangen AöR includes systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myositis, and progressive systemic autoimmune disease resistant to B cell depletion. Additional work covers psoriatic arthritis, axial spondyloarthritis, and early rheumatoid arthritis.

CAR-T cell therapy for refractory autoimmune disease
JAK inhibition in inflammatory joint disease
Interleukin-targeted therapy in psoriatic arthritis
Immunosuppressive tapering in stable disease control

The sponsor also studies enthesitis and pain processing in inflammatory arthritis, with interest in treatment-resistant immune-mediated conditions.

About Specializations

Universitaetsklinikum Erlangen AöR runs clinical trials in conditions such as Psoriatic arthropathy, Chronic kidney disease, Systemic scleroderma, Systemic lupus erythematosus, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

13 clinical trials

Mitral valve disease+2

Recruiting

Study of SP16 to Prevent Acute Kidney Injury in Patients with Chronic Kidney Disease Undergoing Heart Surgery with Heart-Lung Machine

Registered drug

Study of SP16 to Prevent Acute Kidney Injury in Patients with Chronic Kidney Disease Undergoing Heart Surgery with Heart-Lung Machine

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:SP16
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Systemic scleroderma+3

Recruiting

A Study of Idecabtagene Vicleucel CAR-T Cell Therapy for Patients with Autoimmune Diseases That Did Not Respond to B Cell Removal Treatment

Registered drugNo placebo

A Study of Idecabtagene Vicleucel CAR-T Cell Therapy for Patients with Autoimmune Diseases That Did Not Respond to B Cell Removal Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Idecabtagene Vicleucel
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Systemic scleroderma+2

Recruiting

Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis

Registered drugNo placebo

Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Aldesleukin
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Chronic kidney disease

Recruiting

Study on the Effects of Dapagliflozin on Kidney Health in Patients with Chronic Kidney Disease After Kidney Transplantation

Registered drugNo placebo

Study on the Effects of Dapagliflozin on Kidney Health in Patients with Chronic Kidney Disease After Kidney Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Hypoplastic left heart syndrome

Recruiting

Oxygen Therapy for Pregnant Women to Support Heart Development in Unborn Babies with Underdeveloped Left Heart Structures

Registered drugNo placebo

Oxygen Therapy for Pregnant Women to Support Heart Development in Unborn Babies with Underdeveloped Left Heart Structures

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Oxygen
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Psoriatic arthropathy

Recruiting

Study on the Effect of Guselkumab for Treating Enthesitis in Patients with Psoriatic Arthritis Who Have Not Used Biologic DMARDs

Registered drugNo placebo

Study on the Effect of Guselkumab for Treating Enthesitis in Patients with Psoriatic Arthritis Who Have Not Used Biologic DMARDs

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Guselkumab
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Psoriatic arthropathy

Recruiting

Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

Registered drugNo placebo

Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abatacept
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Colitis ulcerative

Not yet recruiting

Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis

InvestigationalNo placebo

Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
Sponsor:Universitaetsklinikum Erlangen AöR